You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Novartis’ rare renal disease candidate shows promise in phase II

Interim analysis results for Novartis’ rare renal disease candidate iptacopan proved promising in a phase II study of the investigational drug.